Join our daily newsletter At The Bell to receive exclusive market insights
- Creso Pharma’s (CPH) Canadian-based psychedelics company Halucenex Life Sciences completes recruitment for its phase two clinical trial
- The trial will test the efficacy of psilocybin on people with treatment-resistant Post Traumatic Stress Disorder (PTSD)
- Halucenex will use its Lucenex branded 10 and 25 milligram synthetic psilocybin product formulation throughout the trial
- A total of 20 patients have been recruited and consist of veterans, firefighters, psychologists, and emergency medical responders
- Creso Pharma has ended the day steady on the market with shares closing at 3.2 cents
Creso Pharma’s (CPH) Canadian-based psychedelics company Halucenex Life Sciences has completed recruitment for its phase two clinical trial.
The trial will test the efficacy of psilocybin on people with treatment-resistant Post Traumatic Stress Disorder (PTSD). It has been designed to be single-arm and open-lab.
Halucenex will use its Lucenex branded 10 and 25 milligram synthetic psilocybin product formulation throughout the trial.
A total of 20 patients have been recruited and consist of veterans, firefighters, psychologists, and emergency medical responders, to name a few.
While everyone in the trial suffers from PTSD, they also suffer from other mental illnesses such as ADHD, depression, anger, anxiety and suicidal thoughts.
The trial will begin on October 12 and is expected to be completed by December 14.
“Halucenex will now begin preparing its relevant treatment facilities for first dosages, which will be administered within the next two weeks,” Halucenex Founder and CEO Bill Fleming said.
Clinical trial participants will be closely monitored closely and in line with all Health Canada regulations,” Mr Fleming added.
“We look forward to providing additional updates as the trial commences, initial dosages are administered and ultimately, interim results that will highlight how synthetic psilocybin can be used to treat such a debilitating condition.”
Creso Pharma was steady on the market with shares trading at 3.2 cents at market close.
